Literature DB >> 14688494

Meeting the challenge to improve the treatment of hypertension in blacks.

Antonio Alberto Lopes1, Sherman A James, Friedrich K Port, Akinlolu O Ojo, Lawrence Y Agodoa, Kenneth A Jamerson.   

Abstract

Hypertension is more prevalent and severe in African descendent populations living outside Africa than in any other population. Given this greater burden of hypertension in blacks, it is increasingly necessary to refine strategies to prevent the disorder as well as improve its treatment and control. This review assesses results from clinical trials on lifestyle and pharmacologic interventions to identify which approaches most effectively prevent adverse hypertension-related outcomes in African descendent populations. The Dietary Approaches to Stop Hypertension (DASH) study provided evidence that a carefully controlled diet rich in fruits, vegetables, low-fat dairy foods, and reduced in saturated fat, total fat, and cholesterol (i.e., the DASH diet) reduces blood pressure in blacks and is well accepted. The combination of the DASH diet with reduction in dietary sodium below 100 mmol/d may provide a reduction in blood pressure beyond that reached by the DASH diet alone. Physical exercise and interventions to reduce psychological stress may also reduce blood pressure in blacks. Strong evidence from numerous studies is a compelling argument for continuing to recommend diuretics and beta blockers as first-line antihypertensive therapy for persons of all races. Some new studies also favor angiotensin-converting enzyme inhibitors as first-line antihypertensive drugs. The African American Study of Kidney Disease and Hypertension provided evidence that an angiotensin-converting enzyme inhibitor-based treatment program is more beneficial than calcium channel blockers and beta blockers in reducing the progression of renal failure in blacks with hypertensive nephropathy. Studies in patients with diabetes have also shown evidence that both angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists are more effective than other classes of antihypertensives in reducing adverse renal events. Studies to evaluate the effects of the new antihypertensives in improving outcomes in blacks living outside the United States are needed.

Entities:  

Mesh:

Year:  2003        PMID: 14688494      PMCID: PMC8101878          DOI: 10.1111/j.1524-6175.2003.01736.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  57 in total

Review 1.  Use of beta-adrenergic receptor blockers in blacks.

Authors:  L M Prisant; G A Mensah
Journal:  J Clin Pharmacol       Date:  1996-10       Impact factor: 3.126

2.  Evaluation of the medical care of patients with hypertension in an emergency department and in ambulatory hypertension unit.

Authors:  Fernando Nobre; Fause Chauchar; Jaciara Machado Viana; Gustavo José Veras Pereira; Nereida Kilza da Costa Lima
Journal:  Arq Bras Cardiol       Date:  2002-02       Impact factor: 2.000

3.  Malignant hypertension: the Brazilian experience.

Authors:  O Ramos
Journal:  Kidney Int       Date:  1984-08       Impact factor: 10.612

4.  Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT).

Authors:  M J Brown; C R Palmer; A Castaigne; P W de Leeuw; G Mancia; T Rosenthal; L M Ruilope
Journal:  Lancet       Date:  2000-07-29       Impact factor: 79.321

5.  Black-white differences in stroke incidence in a national sample. The contribution of hypertension and diabetes mellitus.

Authors:  S J Kittner; L R White; K G Losonczy; P A Wolf; J R Hebel
Journal:  JAMA       Date:  1990-09-12       Impact factor: 56.272

6.  Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial.

Authors:  L Y Agodoa; L Appel; G L Bakris; G Beck; J Bourgoignie; J P Briggs; J Charleston; D Cheek; W Cleveland; J G Douglas; M Douglas; D Dowie; M Faulkner; A Gabriel; J Gassman; T Greene; Y Hall; L Hebert; L Hiremath; K Jamerson; C J Johnson; J Kopple; J Kusek; J Lash; J Lea; J B Lewis; M Lipkowitz; S Massry; J Middleton; E R Miller; K Norris; D O'Connor; A Ojo; R A Phillips; V Pogue; M Rahman; O S Randall; S Rostand; G Schulman; W Smith; D Thornley-Brown; C C Tisher; R D Toto; J T Wright; S Xu
Journal:  JAMA       Date:  2001-06-06       Impact factor: 56.272

7.  Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group.

Authors:  G Viberti; C E Mogensen; L C Groop; J F Pauls
Journal:  JAMA       Date:  1994-01-26       Impact factor: 56.272

8.  Randomised controlled trial of a no-added-sodium diet for mild hypertension.

Authors:  T C Beard; H M Cooke; W R Gray; R Barge
Journal:  Lancet       Date:  1982-08-28       Impact factor: 79.321

9.  Impact of race on treatment response and cardiovascular disease among hypertensives.

Authors:  W L Ooi; N S Budner; H Cohen; S Madhavan; M H Alderman
Journal:  Hypertension       Date:  1989-09       Impact factor: 10.190

10.  Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group.

Authors:  L Hansson; A Zanchetti; S G Carruthers; B Dahlöf; D Elmfeldt; S Julius; J Ménard; K H Rahn; H Wedel; S Westerling
Journal:  Lancet       Date:  1998-06-13       Impact factor: 79.321

View more
  2 in total

1.  The faith, activity, and nutrition (FAN) program: design of a participatory research intervention to increase physical activity and improve dietary habits in African American churches.

Authors:  Sara Wilcox; Marilyn Laken; Allen W Parrott; Margaret Condrasky; Ruth Saunders; Cheryl L Addy; Rebecca Evans; Meghan Baruth; May Samuel
Journal:  Contemp Clin Trials       Date:  2010-03-30       Impact factor: 2.226

2.  Diabetes, body fat, skeletal muscle, and hypertension: The ominous chiasmus?

Authors:  Jun Shu; Alessandro Matarese; Gaetano Santulli
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-12-07       Impact factor: 3.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.